

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 5**
May 2012



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 5

May 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 5
May 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711			
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)			
MULTISOURCE	11953 (82.5%)	12187 (82.8%)			
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)			
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)			
EXCEPTIONS ¹	76 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES					
APPROVED	6	8			
NUMBER OF APPLICANTS	810	826			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
----	---------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

CAPITAL AND CODEINE

	+ VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
--	-----------	--------------------	-------------	--	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
----	------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
----	-------------	--------------	-------------	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Apr	NEWA
AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
	DIAMOX					
	@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	@ BELCHER PHARMS	200MG	A074889 001	Oct 31, 1997	May	CAHN
>A>	@ HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997	May	CAHN

TABLET; ORAL

ACYCLOVIR

>D>	@ BELCHER PHARMS	400MG	A074891 001	Oct 31, 1997	May	CAHN
>D>	@	800MG	A074891 002	Oct 31, 1997	May	CAHN

TABLET; ORAL

ACYCLOVIR

>A>	@ HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997	May	CAHN
>A>	@	800MG	A074891 002	Oct 31, 1997	May	CAHN

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
---	------------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@	TEVA PARENTERAL	3MG/ML	A078676 001	Jul 31, 2008	Mar	DISC
---	-----------------	--------	-------------	--------------	-----	------

@		3MG/ML	A076564 001	Jun 16, 2004	Jan	DISC
---	--	--------	-------------	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@	SANDOZ INC	EQ 0.083% BASE;0.017%	A076867 001	Dec 21, 2006	Apr	DISC
---	------------	-----------------------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076973 001	Jul 12, 2005	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076884 001	Jul 18, 2005	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+	MISSION PHARMA	EQ 70MG BASE	N202344 001	Mar 12, 2012	Mar	NEWA
---	----------------	--------------	-------------	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	INVAGEN PHARMS	10MG	A090284 001	Jan 17, 2012	Jan	NEWA
----	----------------	------	-------------	--------------	-----	------

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@	GENZYME	80 UNITS/ML	N020057 003	Apr 05, 1991	Mar	DISC
---	---------	-------------	-------------	--------------	-----	------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@	SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006	Mar	DISC
---	------------	-------	-------------	--------------	-----	------

@		1MG	A077777 002	Jun 30, 2006	Mar	DISC
---	--	-----	-------------	--------------	-----	------

@		2MG	A077777 003	Jun 30, 2006	Mar	DISC
---	--	-----	-------------	--------------	-----	------

@		3MG	A077777 004	Jun 30, 2006	Mar	DISC
---	--	-----	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726 001	Jan 19, 2005	Jan	CAHN
AB		0.5MG	N021726 002	Jan 19, 2005	Jan	CAHN
AB	+	1MG	N021726 003	Jan 19, 2005	Jan	CAHN
AB		2MG	N021726 004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+	CUBIST PHARMS	12MG	N021775 001	May 20, 2008	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065 001	May 15, 2003	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

AMCINONIDE

+	FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096 001	Nov 19, 2002	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

15%(150GM/1000ML)

A091112 001 Apr 13, 2012 Mar NEWA

15%(300GM/2000ML)

A091112 002 Apr 13, 2012 Mar NEWA

NOVAMINE 15%

@ HOSPIRA INC

15% (75GM/500ML)

N017957 004 Nov 28, 1986 Mar CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS

250MG/ML

N015229 002 Mar CAHN

SYRUP; ORAL

AMICAR

AA	+	CLOVER PHARMS	1.25GM/5ML	N015230 002	Mar	CAHN
----	---	---------------	------------	-------------	-----	------

TABLET; ORAL

AMICAR

AB		CLOVER PHARMS	500MG	N015197 001	Mar	CAHN
----	--	---------------	-------	-------------	-----	------

+		1GM	N015197 002	Jun 24, 2004	Mar	CAHN
---	--	-----	-------------	--------------	-----	------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A076163 001 Sep 05, 2003 Jan DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>D>	AB	AUROSAL PHARMS	200MG	A077069 001	Apr 08, 2005	May	CAHN
-----	----	----------------	-------	-------------	--------------	-----	------

>D>	AB		400MG	A077069 002	Apr 08, 2005	May	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB	MURTY PHARMS	200MG	A077069 001	Apr 08, 2005	May	CAHN
-----	----	--------------	-------	-------------	--------------	-----	------

>A>	AB		400MG	A077069 002	Apr 08, 2005	May	CAHN
-----	----	--	-------	-------------	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CARACO	10MG	A040816 002	Jun 27, 2008	Apr	NEWA
AB		50MG	A040816 003	Jun 27, 2008	Apr	NEWA
AB		75MG	A040816 004	Jun 27, 2008	Apr	NEWA
AB		100MG	A040816 005	Jun 27, 2008	Apr	NEWA
AB		150MG	A040816 006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC
+		EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
	LIMBITROL					
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
	LIMBITROL DS					
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
--	--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

>D>	+	ALDOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
>D>	+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN
>A>	+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
>A>	+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
	ANAGRELIDE HYDROCHLORIDE					
	@ SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
	@	EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	APOTEX INC	1MG	A200654	001	May 11, 2012	Apr	NEWA
>A>	AB	IMPAX LABS INC	1MG	A091242	001	May 31, 2012	May NEWA

>D> APROTININ

>D> INJECTABLE; INJECTION

>D> TRASYLOL

>D>	+	BAYER HLTHCARE	10,000KIU/ML	N020304	001	Dec 29, 1993	May DISC
-----	---	----------------	--------------	---------	-----	--------------	----------

>A>	@		10,000KIU/ML	N020304	001	Dec 29, 1993	May DISC
-----	---	--	--------------	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jan CTNA
----	---	--------	------------------------	---------	-----	--------------	----------

ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Jan NEWA
----	--	--------------------	------------------------	---------	-----	--------------	----------

ARMODAFINIL

TABLET; ORAL

>A> ARMODAFINIL

>A>	AB	MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	May NEWA
-----	----	------------------	------	---------	-----	--------------	----------

>A>	AB		150MG	A200043	002	Jun 01, 2012	May NEWA
-----	----	--	-------	---------	-----	--------------	----------

>A>	AB		250MG	A200043	003	Jun 01, 2012	May NEWA
-----	----	--	-------	---------	-----	--------------	----------

NUVIGIL

>D>		CEPHALON	50MG	N021875	001	Jun 15, 2007	May CFTG
-----	--	----------	------	---------	-----	--------------	----------

>A>	AB		50MG	N021875	001	Jun 15, 2007	May CFTG
-----	----	--	------	---------	-----	--------------	----------

>D>			150MG	N021875	003	Jun 15, 2007	May CFTG
-----	--	--	-------	---------	-----	--------------	----------

>A>	AB		150MG	N021875	003	Jun 15, 2007	May CFTG
-----	----	--	-------	---------	-----	--------------	----------

>D>	+		250MG	N021875	004	Jun 15, 2007	May CFTG
-----	---	--	-------	---------	-----	--------------	----------

>A>	AB	+	250MG	N021875	004	Jun 15, 2007	May CFTG
-----	----	---	-------	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145	001	Jan 25, 2012	Jan NEWA
----	--	----------------	---	---------	-----	--------------	----------

MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	N021881	001	Aug 02, 2006	Jan CFTG
----	---	--------------	---	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb CAHN
----	--	-------------	-------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb CAHN
----	--	-------------	------------------	---------	-----	--------------	----------

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

>A>	AB	APOTEX INC	EQ 10MG BASE	A090548 001	May 29, 2012	May	NEWA
>A>	AB		EQ 20MG BASE	A090548 002	May 29, 2012	May	NEWA
>A>	AB		EQ 40MG BASE	A090548 003	May 29, 2012	May	NEWA
>A>	AB		EQ 80MG BASE	A090548 004	May 29, 2012	May	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226 001	May 29, 2012	May	NEWA
>A>	AB		EQ 20MG BASE	A091226 002	May 29, 2012	May	NEWA
>A>	AB		EQ 40MG BASE	A091226 003	May 29, 2012	May	NEWA
>A>	AB		EQ 80MG BASE	A091226 004	May 29, 2012	May	NEWA
>A>	AB	SANDOZ INC	EQ 10MG BASE	A077575 001	May 29, 2012	May	NEWA
>A>	AB		EQ 20MG BASE	A077575 002	May 29, 2012	May	NEWA
>A>	AB		EQ 40MG BASE	A077575 003	May 29, 2012	May	NEWA
>A>	AB		EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
>A>	AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
>A>	AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
>A>	AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
>A>	AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

		50MG	N202276 001	Apr 27, 2012	Apr	NEWA
		100MG	N202276 002	Apr 27, 2012	Apr	NEWA
+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

		1MG	N202324 001	Jan 27, 2012	Jan	NEWA
+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

>A>	AT	ALCON PHARMA	0.05%	A202305 001	May 31, 2012	May	NEWA
-----	----	--------------	-------	-------------	--------------	-----	------

SPRAY, METERED; NASAL
AZELASTINE HYDROCHLORIDE

>A> AB SUN PHARMA GLOBAL EQ 0.125MG BASE/SPRAY A090423 001 May 23, 2012 May NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

>A> SPRAY, METERED; NASAL

>A> DYMISTA

>A> + MEDA PHARMS EQ 0.125MG
BASE/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 May NEWA

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS USA EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Apr CAHN

+ EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Apr CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

TAKEDA PHARMS USA EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Apr CAHN

+ EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Apr CAHN

BACLOFEN

TABLET; ORAL

BACLOFEN

AB PROSAM LABS 10MG

A077089 001 Oct 31, 2007 Feb CAHN

AB 20MG

A077088 001 Oct 31, 2007 Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@ UCB INC 10MG

N021589 001 Oct 30, 2003 Jan CAHN

@ 20MG

N021589 002 Oct 30, 2003 Jan CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+ SALIX PHARMS 1.1GM

N022205 001 Feb 03, 2012 Feb NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+ TEVA BRANDED PHARM 0.08MG/ACTIVATION

N202813 001 Mar 23, 2012 Mar NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB VALEANT INTL 5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Apr CAHN

BT + 5%;EQ 1% BASE

N050756 002 Apr 20, 2007 Apr CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB + VALEANT INTL 5%;3%

N050557 001 Oct 26, 1984 Jan CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012	Jan	NEWA
----	-------------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

>A>	AP	APP PHARMS LLC	1MG/ML	A090233 001	Jul 28, 2009	May	CAHN
-----	----	----------------	--------	-------------	--------------	-----	------

>D>	AP	NEXUS PHARMS	1MG/ML	A090233 001	Jul 28, 2009	May	CAHN
-----	----	--------------	--------	-------------	--------------	-----	------

COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015 001		Feb	CAHN
----	---	------------------	--------	-------------	--	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ LANNETT HOLDINGS INC 0.5MG

A088877 001 Apr 11, 1985 Jan DISC

@ 1MG

A088894 001 Apr 11, 1985 Jan DISC

@ 2MG

A088895 001 Apr 11, 1985 Jan DISC

AA PROSAM LABS 0.5MG

A040699 001 Feb 14, 2008 Feb CMFD

AA 1MG

A040705 001 Feb 14, 2008 Feb CMFD

AA 2MG

A040706 001 Feb 14, 2008 Feb CMFD

AA + USL PHARMA 0.5MG

A040103 001 Dec 12, 1996 Jan CRLD

AA + 1MG

A040103 002 Dec 12, 1996 Jan CRLD

AA + 2MG

A040103 003 Dec 12, 1996 Jan CRLD

>D> BETAMETHASONE

>D> SYRUP; ORAL

>D> CELESTONE

>D>	+	SCHERING	0.6MG/5ML	N014215 002		May	DISC
-----	---	----------	-----------	-------------	--	-----	------

>A>	@	0.6MG/5ML	N014215 002		May	DISC
-----	---	-----------	-------------	--	-----	------

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137 001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	-------------	--------------	-----	------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215 001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276 001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	-------------	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502 001	Jun 05, 2001	Jan	CAHN
----	--	----------------	------------------	-------------	--------------	-----	------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516 001	Jun 16, 2005	Jan	CAHN
----	--	----------------	------------------	-------------	--------------	-----	------

LOTION; TOPICAL

LOTTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010 001	Dec 08, 2000	Feb	CAHN
----	---	---------------	------------------	-------------	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

	+	STIEFEL	EQ 0.12% BASE	N020934 001	Feb 28, 1999	Jan	CAHN
--	---	---------	---------------	-------------	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB		TEVA WOMENS	5MG	N019982 002	Jul 31, 1992	Jan	CAHN
----	--	-------------	-----	-------------	--------------	-----	------

AB	+		10MG	N019982 001	Jul 31, 1992	Jan	CAHN
----	---	--	------	-------------	--------------	-----	------

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

	+	MERCK SHARP DOHME	200MG	N202258 001	May 13, 2011	Mar	CAHN
--	---	-------------------	-------	-------------	--------------	-----	------

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602 001	May 13, 2003	Jan	CDFR
--	---	-------------------	------------	-------------	--------------	-----	------

BOSENTAN

TABLET; ORAL

TRACLEER

>D>		ACTELION	62.5MG	N021290 001	Nov 20, 2001	May	CAHN
-----	--	----------	--------	-------------	--------------	-----	------

>D>	+		125MG	N021290 002	Nov 20, 2001	May	CAHN
-----	---	--	-------	-------------	--------------	-----	------

>A>		ACTELION PHARMS LTD	62.5MG	N021290 001	Nov 20, 2001	May	CAHN
-----	--	---------------------	--------	-------------	--------------	-----	------

>A>	+		125MG	N021290 002	Nov 20, 2001	May	CAHN
-----	---	--	-------	-------------	--------------	-----	------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929 001	Jul 21, 2006	Jan	CDFR
--	---	-------------	-------------------------	-------------	--------------	-----	------

	+		0.16MG/INH;0.0045MG/INH	N021929 002	Jul 21, 2006	Jan	CDFR
--	---	--	-------------------------	-------------	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
--	--	-------------------	---------------------------	-------------	--------------	-----	------

	+		EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN
--	---	--	-------------------------	-------------	--------------	-----	------

TABLET; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
--	--	-------------------	---------------------------	-------------	--------------	-----	------

	+		EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT
--	---	--	-------------------------	-------------	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

	+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
--	---	---------------------	-------	-------------	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

	@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
	@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
	@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
	@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
	@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
	@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
	@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
AB		5MG	A075388 001	May 09, 2002	Feb	CMFD
	@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
	@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

	@ PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Apr	NEWA
--	------------------	----	-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	---	--------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	---	--------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

>A>	AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
-----	----	--------	--------	-------------	--------------	-----	------

DOVONEX

>D>	+	LEO PHARM	0.005%	N020554 001	Jul 22, 1996	May	CFTG
-----	---	-----------	--------	-------------	--------------	-----	------

>A>	AB	+	LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
-----	----	---	---------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

>A>	AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
-----	----	-------------	------------------	-------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
----	--	-------------------	------------------	-------------	--------------	-----	------

AB			37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
----	--	--	--------------------	-------------	--------------	-----	------

STALEVO 100

AB		ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
----	--	--------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

STALEVO 150

AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
----	--------------	--------------------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
>A>	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
>A>		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
>A>		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA

PARAPLATIN

@ CORDEN PHARMA

@

@

	50MG/VIAL	N019880 001	Mar 03, 1989	Feb	CAHN
	150MG/VIAL	N019880 002	Mar 03, 1989	Feb	CAHN
	450MG/VIAL	N019880 003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

@

	EQ 250MG BASE	A064156 001	Aug 28, 1997	Apr	DISC
	EQ 500MG BASE	A064156 002	Aug 28, 1997	Apr	DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

		EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
	@	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
	@	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
	@	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA

FOR SUSPENSION; ORAL

CEFACLOR

AB	YUNG SHIN PHARM	EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
AB		EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
AB		EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003 Apr DISC

@

EQ 187MG BASE

A065092 002 Dec 22, 2003 Apr DISC

@

EQ 250MG BASE

A065092 003 Dec 22, 2003 Apr DISC

@

EQ 375MG BASE

A065092 004 Dec 22, 2003 Apr DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD

EQ 500MG BASE

A065015 001 Jun 22, 1999 Apr DISC

TABLET; ORAL

CEFADROXIL

@ RANBAXY

EQ 1GM BASE

A065018 001 Apr 23, 1999 Apr DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

>A>

B BRAUN

EQ 2GM BASE/VIAL

N050779 003 Jan 13, 2012 May NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

200MG

N021222 001 Aug 29, 2001 Mar CAHN

+

400MG

N021222 002 Jul 21, 2008 Mar CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP + SANOFI AVENTIS US

EQ 1GM BASE/VIAL

A062659 001 Jan 13, 1987 Mar CRLD

AP +

EQ 2GM BASE/VIAL

A062659 002 Jan 13, 1987 Mar CRLD

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB APOTEX INC

125MG/5ML

A065351 001 Feb 29, 2012 Feb NEWA

AB

250MG/5ML

A065351 002 Feb 29, 2012 Feb NEWA

@ RANBAXY LABS LTD

125MG/5ML

A065202 001 Jun 30, 2006 Apr DISC

@

250MG/5ML

A065202 002 Jun 30, 2006 Apr DISC

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006 Apr DISC

@

500MG

A065198 002 Dec 13, 2006 Apr DISC

CEFZIL

@ CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991 Feb CAHN

@

500MG

N050664 002 Dec 23, 1991 Feb CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP + COVIS PHARMA

500MG/VIAL

N050578 001 Jul 19, 1985 Apr CAHN

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

		@ COVIS PHARMA	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
	+		EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
	+		EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

		@ RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
		@	EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
		@	EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
----	---	--------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZINACEF

AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN

ZINACEF IN PLASTIC CONTAINER

	+	COVIS PHARMA	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989	Apr	CAHN
	+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989	Apr	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA		SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA
----	--	--------	---------	-------------	--------------	-----	------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

>A>	+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
>D>	+	PBS	2MG	N010669 002		May	CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

>A>		NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
>D>		NYCOMED US	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

	+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
--	---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

>A>	+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
-----	---	--------------	------------	-------------	--------------	-----	------

>D>	+	NYCOMED US	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
-----	---	------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

AB		GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA
----	--	-------------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CICLOPIROX

AT		FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT		MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	--	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

	@	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
--	---	-----------------	----------------------	-------------	--------------	-----	------

	@		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC
--	---	--	----------------------	-------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

	@	PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
--	---	-------	---------------	-------------	--------------	-----	------

	@		EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
--	---	--	---------------	-------------	--------------	-----	------

	@		EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
--	---	--	---------------	-------------	--------------	-----	------

	@		EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC
--	---	--	---------------	-------------	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB		DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP		SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
----	--	------------	----------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
----	--	------------	----------------	-------------	--------------	-----	------

AP			EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
----	--	--	-----------------	-------------	--------------	-----	------

NIMBEX

AP	+	ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
----	---	--------	----------------	-------------	--------------	-----	------

NIMBEX PRESERVATIVE FREE

AP	+	ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
----	---	--------	----------------	-------------	--------------	-----	------

INJECTABLE; INJECTION
NIMBEX PRESERVATIVE FREE

AP + ABBOTT EQ 10MG BASE/ML N020551 002 Dec 15, 1995 Jan CFTG

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN

AP ONCO THERAPIES LTD 1MG/ML A091062 001 Apr 18, 2012 Apr NEWA
@ TEVA PARENTERAL 1MG/ML A074814 001 May 16, 2000 Mar DISC

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLINDAMYCIN PHOSPHATE

AB FOUGERA PHARMS EQ 2% BASE A065139 001 Dec 27, 2004 Jan CAHN

GEL; TOPICAL
CLINDAMYCIN PHOSPHATE

AB FOUGERA PHARMS EQ 1% BASE A064160 001 Jan 28, 2000 Jan CAHN

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> + PHARMACIA AND UPJOHN EQ 6MG BASE/ML N050639 001 Aug 30, 1989 May CFTG
>A> AP + EQ 6MG BASE/ML N050639 001 Aug 30, 1989 May CFTG
>D> + EQ 12MG BASE/ML N050639 002 Aug 30, 1989 May CFTG
>A> AP + EQ 12MG BASE/ML N050639 002 Aug 30, 1989 May CFTG
>D> + EQ 18MG BASE/ML N050639 003 Apr 10, 1991 May CFTG
>A> AP + EQ 18MG BASE/ML N050639 003 Apr 10, 1991 May CFTG

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

>A> AP SANDOZ INC EQ 6MG BASE/ML A201692 001 May 31, 2012 May NEWA
>A> AP EQ 12MG BASE/ML A201692 002 May 31, 2012 May NEWA
>A> AP EQ 18MG BASE/ML A201692 003 May 31, 2012 May NEWA

LOTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AB FOUGERA PHARMS EQ 1% BASE A065067 001 Jan 31, 2002 Jan CAHN

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT FOUGERA PHARMS EQ 1% BASE A065254 001 Feb 14, 2006 Jan CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL
VELTIN

>D> BX STIEFEL GSK 1.2%;0.025% N050803 001 Jul 16, 2010 May CRLD
>A> BX + 1.2%;0.025% N050803 001 Jul 16, 2010 May CRLD

CLOBAZAM

TABLET; ORAL
ONFI

LUNDBECK LLC 5MG
10MG
+ 20MG

N202067 001 Oct 21, 2011 Mar CAHN
N202067 002 Oct 21, 2011 Mar CAHN
N202067 003 Oct 21, 2011 Mar CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)

AB2 FOUGERA PHARMS 0.05% A075430 001 May 26, 1999 Jan CAHN

TEMOVATE

AB1 + FOUGERA PHARMS 0.05% N019322 001 Dec 27, 1985 Jan CAHN

GEL; TOPICAL

CLOBETASOL PROPIONATE									
AB	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	Jan	CAHN		
TEMOVATE									
AB	+ FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	Jan	CAHN		
OINTMENT; TOPICAL									
CLOBETASOL PROPIONATE									
AB	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Jan	CAHN		
TEMOVATE									
AB	+ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CAHN		
SOLUTION; TOPICAL									
CLOBETASOL PROPIONATE									
AT	FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN		
TEMOVATE									
AT	+ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN		

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN		
AP	+	5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN		

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

>D>	@ SHIONOGI INC	0.2MG	N022331	004	Sep 28, 2010	May	CMFD		
>A>		0.2MG	N022331	004	Sep 28, 2010	May	CMFD		

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012	Apr	NEWA		
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr	NEWA		
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD		
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr	NEWA		
AB	GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012	Apr	NEWA		
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Apr	NEWA		
AB		EQ 300MG BASE	A077665	002	May 17, 2012	Apr	NEWA		
AB	ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Apr	NEWA		
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012	Apr	NEWA		
AB	TEVA	EQ 75MG BASE	A076999	001	May 17, 2012	Apr	NEWA		
AB	TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012	Apr	NEWA		
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012	Apr	NEWA		
PLAVIX									
AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC		
AB	+	EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr	CTEC		

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ LUNDBECK LLC

@

@

		3.75MG	N017105	001		Mar	CAHN		
		7.5MG	N017105	002		Mar	CAHN		
		15MG	N017105	003		Mar	CAHN		

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105	006		Mar	CAHN		
AB		7.5MG	N017105	007		Mar	CAHN		
AB	+	15MG	N017105	008		Mar	CAHN		

TABLET; ORAL

TRANXENE SD

@ LUNDBECK LLC

11.25MG

N017105 005

Mar CAHN

@

22.5MG

N017105 004

Mar CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

AB

FOUGERA PHARMS

1%

A078338 001 Sep 02, 2008 Jan CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ

12.5MG

N021590 004 May 30, 2007 Apr CAHN

25MG

N021590 001 Feb 10, 2004 Apr CAHN

@

50MG

N021590 003 Jun 03, 2005 Apr CAHN

+

100MG

N021590 002 Feb 10, 2004 Apr CAHN

150MG

N021590 005 Jul 09, 2010 Apr CAHN

200MG

N021590 006 Jul 09, 2010 Apr CAHN

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

>D>

+

DURAMED RES

309MG/COPPER

N018680 001 Nov 15, 1984 May CAHN

>A>

+

TEVA WOMENS

309MG/COPPER

N018680 001 Nov 15, 1984 May CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

AA

+

JAZZ PHARMS COMMERCL 100MG/5ML

N020479 001 Feb 29, 1996 Mar CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB

PROSAM LABS

5MG

A077291 001 Feb 03, 2006 Feb CAHN

AB

10MG

A077209 001 Oct 04, 2005 Feb CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP

+

BAXTER HLTHCARE

500MG/VIAL

N012142 003 Apr CRLD

AP

+

1GM/VIAL

N012142 004 Aug 30, 1982 Apr CRLD

AP

+

2GM/VIAL

N012142 005 Aug 30, 1982 Apr CRLD

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

>D>

AB1

PLIVA

25MG

A065044 002 Dec 20, 2000 May CAHN

>D>

AB1

100MG

A065044 001 Dec 20, 2000 May CAHN

>A>

AB1

WATSON LABS INC

25MG

A065044 002 Dec 20, 2000 May CAHN

>A>

AB1

100MG

A065044 001 Dec 20, 2000 May CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP

ONCO THERAPIES LTD

100MG/ML

A201784 001 Jan 30, 2012 Jan NEWA

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		Mar	CAHN
----	---	--------------	------------	-------------	--	-----	------

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL
PREZISTA

+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011	Feb	CAHN
---	---------------	------------------	-------------	--------------	-----	------

TABLET; ORAL
PREZISTA

JANSSEN PRODS	EQ 75MG BASE	N021976 004	Dec 18, 2008	Feb	CAHN
---------------	--------------	-------------	--------------	-----	------

	EQ 150MG BASE	N021976 005	Dec 18, 2008	Feb	CAHN
--	---------------	-------------	--------------	-----	------

@	EQ 300MG BASE	N021976 001	Jun 23, 2006	Feb	CAHN
---	---------------	-------------	--------------	-----	------

	EQ 400MG BASE	N021976 003	Oct 21, 2008	Feb	CAHN
--	---------------	-------------	--------------	-----	------

+	EQ 600MG BASE	N021976 002	Feb 25, 2008	Feb	CAHN
---	---------------	-------------	--------------	-----	------

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB	BELCHER PHARMS	5MG	A078355 001	Apr 19, 2012	Apr	NEWA
----	----------------	-----	-------------	--------------	-----	------

AB	MYLAN PHARMS INC	5MG	A078351 001	Feb 10, 2012	Jan	NEWA
----	------------------	-----	-------------	--------------	-----	------

DESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB	+	SANOFI AVENTIS US	0.01%	N017922 001		Mar	CFTG
----	---	-------------------	-------	-------------	--	-----	------

DESMOPRESSIN ACETATE

AB	SUN PHARM INDS	0.01%	A077212 001	Apr 12, 2012	Mar	NEWA
----	----------------	-------	-------------	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

VIORLE

AB	GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346 001	Apr 02, 2012	Mar	NEWA
----	-------------------	--------------------------	-------------	--------------	-----	------

DESONIDE

LOTION; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075860 001	Mar 19, 2002	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075751 001	Mar 12, 2001	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	0.25%	A078369 001	Jun 29, 2010	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TOPICORT

+	TARO	0.05%	A073210 001	Nov 30, 1990	Apr	CTNA
---	------	-------	-------------	--------------	-----	------

+		0.25%	A073193 001	Nov 30, 1990	Apr	CTNA
---	--	-------	-------------	--------------	-----	------

@	TARO PHARMS NORTH	0.25%	N017856 001		Apr	DISC
---	-------------------	-------	-------------	--	-----	------

TOPICORT LP

@	TARO PHARMS NORTH	0.05%	N018309 001		Apr	DISC
---	-------------------	-------	-------------	--	-----	------

GEL; TOPICAL						
TOPICORT						
AB	+	TARO	0.05%	A074904 001	Jul 14, 1998 Apr	CTNA
		@ TARO PHARMS NORTH	0.05%	N018586 001	Mar 29, 1982 Apr	DISC
OINTMENT; TOPICAL						
DESOXIMETASONE						
AB	+	TARO	0.25%	A074286 001	Jun 07, 1996 Mar	CRLD
TOPICORT						
	+	TARO	0.25%	A074286 001	Jun 07, 1996 Apr	CTNA
		@ TARO PHARMS NORTH	0.25%	N018763 001	Sep 30, 1983 Mar	DISC
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>						
INJECTABLE; INJECTION						
DEXAMETHASONE SODIUM PHOSPHATE						
AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572 001	Apr 22, 2005 Feb	CRLD
<u>DIAZEPAM</u>						
INJECTABLE; INJECTION						
DIAZEPAM						
		@ HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987 Apr	DISC
<u>DIFLORASONE DIACETATE</u>						
CREAM; TOPICAL						
DIFLORASONE DIACETATE						
BX	+	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002 Jan	CAHN
AB1	+		0.05%	A075187 001	Mar 30, 1998 Jan	CAHN
OINTMENT; TOPICAL						
DIFLORASONE DIACETATE						
AB		FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999 Jan	CAHN
<u>DIFLUNISAL</u>						
TABLET; ORAL						
DIFLUNISAL						
AB		EMCURE PHARMS USA	500MG	A202845 001	Mar 08, 2012 Feb	NEWA
AB	+	TEVA	500MG	A073673 001	Jul 31, 1992 Feb	CTEC
<u>DILTIAZEM HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
DILTIAZEM HYDROCHLORIDE						
		@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997 Jan	DISC
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
BENADRYL						
		@ MCNEIL CONS	50MG/ML	N006146 002		Mar DISC
BENADRYL PRESERVATIVE FREE						
		@ MCNEIL CONS	50MG/ML	N009486 001		Mar DISC
DIPHENHYDRAMINE HYDROCHLORIDE						
AP	+	BAXTER HLTHCARE	50MG/ML	A080817 002		Apr CRLD
<u>DIPYRIDAMOLE</u>						
INJECTABLE; INJECTION						
DIPYRIDAMOLE						
		@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997 Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
	TAXOTERE					
AP	+ SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+	80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
---	-------------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	NESHER PHARMS	EQ 1MG BASE
@		EQ 2MG BASE
@		EQ 4MG BASE
@		EQ 8MG BASE

A075609 001	Oct 18, 2000	Feb	DISC
A075609 002	Oct 18, 2000	Feb	DISC
A075609 003	Oct 18, 2000	Feb	DISC
A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
---	----------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

>A>	AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
		@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
		@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

TABLET; ORAL

DOXYCYCLINE

@ SANDOZ INC

@

@

EQ 50MG BASE

EQ 75MG BASE

EQ 100MG BASE

A065353 001 Nov 27, 2006 Mar DISC

A065353 002 Nov 27, 2006 Mar DISC

A065353 003 Nov 27, 2006 Mar DISC

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
----	-------------	--------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
----	---	--------------	---------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA
----	--	------------------	---------------	-------------	--------------	-----	------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

BAYER HLTHCARE

0.25MG;0.5MG

N021355 001 Feb 29, 2012 Feb NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC 200MG;EQ 25MG BASE;300MG

N202123 001 Aug 10, 2011 Apr CAIN

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@ SANDOZ INC

@

@

@

@

@

@

@

@

2.5MG

2.5MG

5MG

5MG

10MG

10MG

20MG

20MG

A075621 001 Aug 22, 2000 Feb DISC

A075496 001 Aug 22, 2000 Jan DISC

A075621 002 Aug 22, 2000 Feb DISC

A075496 002 Aug 22, 2000 Jan DISC

A075621 003 Aug 22, 2000 Feb DISC

A075459 001 Aug 22, 2000 Jan DISC

A075621 004 Aug 22, 2000 Feb DISC

A075459 002 Aug 22, 2000 Jan DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ SANDOZ INC

@

5MG;12.5MG

10MG;25MG

A076116 001 Sep 19, 2001 Mar DISC

A076116 002 Sep 19, 2001 Mar DISC

ENTACAPONE

TABLET; ORAL

COMTAN

>D>	+	ORION	200MG	N020796 001	Oct 19, 1999	May	CAHN
>A>	+	ORION PHARMA	200MG	N020796 001	Oct 19, 1999	May	CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		LUITPOLD	0.05%	A090951 001	Oct 31, 2011	Mar	CAHN
----	--	----------	-------	-------------	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALINE

BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800 003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG /DELIVERY	N020800 004	Nov 25, 2009	Mar	CAHN
		TWINJECT 0.15					
BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800 002	May 28, 2004	Mar	CAHN
		TWINJECT 0.3					
BX	+	COREPHARMA	EQ 0.3MG /DELIVERY	N020800 001	May 30, 2003	Mar	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

>D>	AP	SEPTODONT	0.01MG/ML;2%	A084048 001		May	CRLD
>A>	AP	+	0.01MG/ML;2%	A084048 001		May	CRLD
>D>		XYLOCAINE DENTAL WITH EPINEPHRINE					
>D>	AP	+	DENTSPLY PHARM	0.01MG/ML;2%	N021381 001	May	DISC
>A>		@	0.01MG/ML;2%	N021381 001		May	DISC
>D>	AP	+		0.02MG/ML;2%	N021381 002	May	DISC
>A>		@	0.02MG/ML;2%	N021381 002		May	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	50MG/25ML (2MG/ML)	A065361 001	Oct 22, 2007	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A065361 002	Oct 22, 2007	Mar	CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	CAHN
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012	Mar	NEWA
AP			200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012	Mar	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

>D>	+	ACTELION	EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008	May	CAHN
>A>	+	ACTELION PHARMS LTD	EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008	May	CAHN

ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYCETTE

@ JOHNSON AND JOHNSON 2%

N050594 001 Feb 15, 1985 Apr CAHN

ERYTHROMYCIN

AT + FOUGERA PHARMS 2%

A065320 001 Jul 25, 2006 Jan CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA AMNEAL PHARMS EQ 5MG BASE/5ML

A202227 001 Mar 14, 2012 Feb NEWA

AA AUROBINDO PHARMA LTD EQ 5MG BASE/5ML

A079062 001 Apr 02, 2012 Mar NEWA

>A> AA HETERO LABS LTD III EQ 5MG BASE/5ML

A202221 001 Jun 12, 2012 May NEWA

AA TARO EQ 5MG BASE/5ML

A079121 001 May 03, 2012 Apr NEWA

LEXAPRO

AA + FOREST LABS EQ 5MG BASE/5ML

N021365 001 Nov 27, 2002 Feb CFTG

TABLET; ORAL

ESCITALOPRAM OXALATE

AB IVAX SUB TEVA PHARMS EQ 5MG BASE

A076765 001 Mar 14, 2012 Feb NEWA

AB EQ 10MG BASE

A076765 002 Mar 14, 2012 Feb NEWA

AB EQ 20MG BASE

A076765 003 Mar 14, 2012 Feb NEWA

LEXAPRO

AB FOREST LABS EQ 5MG BASE

N021323 001 Aug 14, 2002 Feb CFTG

AB EQ 10MG BASE

N021323 002 Aug 14, 2002 Feb CFTG

AB + EQ 20MG BASE

N021323 003 Aug 14, 2002 Feb CFTG

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

>D> GALEN LTD EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003 May CAHN

>D> + EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003 May CAHN

>A> WARNER IRELAND EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003 May CAHN

>A> + EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003 May CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB TEVA PHARMS USA 0.5MG;0.1MG

A200747 001 Mar 08, 2012 Feb NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D> AB VINTAGE PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG A077502 001 Nov 23, 2011 May CDFR

>D> AB WATSON LABS 0.02MG;0.09MG A079218 001 Jun 06, 2011 May CRLD

>A> + 0.02MG;0.09MG A079218 001 Jun 06, 2011 May CRLD

>D> LYBREL

>D> AB + WYETH PHARMS INC 0.02MG;0.09MG N021864 001 May 22, 2007 May DISC

>A> @ 0.02MG;0.09MG N021864 001 May 22, 2007 May DISC

TABLET; ORAL-28

FALMINA

AB1 NOVAST LABS LTD 0.02MG;0.1MG A090721 001 Mar 28, 2012 Mar NEWA

MARLISSA

AB GLENMARK GENERICS 0.03MG;0.15MG A091452 001 Feb 29, 2012 Feb NEWA

>A> MYZILRA

>A> AB VINTAGE PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG A077502 001 Nov 23, 2011 May CDFR

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	0.035MG;1MG	A091634 001	Jan 19, 2012	Jan	NEWA
----	-------------------	-------------	-------------	--------------	-----	------

ALYACEN 7/7/7

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636 001	Jan 19, 2012	Jan	NEWA
----	-------------------	--	-------------	--------------	-----	------

WERA

AB	NOVAST LABS LTD	0.035MG;0.5MG	A091204 001	Mar 27, 2012	Mar	NEWA
----	-----------------	---------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

>A>	AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
-----	----	-----------------	----------------	-------------	--------------	-----	------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
----	-------------------	----------------	-------------	--------------	-----	------

>A> TRI-LINYAH

>A>	AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
-----	----	-----------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	-------------	--------------	-----	------

ETODOLAC

TABLET; ORAL

ETODOLAC

AB	PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

AB		500MG	A074819 002	Apr 28, 1998	Feb	CMFD
----	--	-------	-------------	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

@ CORDEN PHARMA

50MG

N019557 001	Dec 30, 1986	Feb	CAHN
-------------	--------------	-----	------

@

100MG

N019557 002	Dec 30, 1986	Feb	CAHN
-------------	--------------	-----	------

INJECTABLE; INJECTION

ETOPOSIDE

AP	+	APP PHARMS LLC	20MG/ML	A074983 001	Sep 30, 1998	Mar	CRLD
----	---	----------------	---------	-------------	--------------	-----	------

AP		BEDFORD	20MG/ML	A074290 001	Jul 17, 1995	Mar	CRLD
----	--	---------	---------	-------------	--------------	-----	------

VEPESID

@ CORDEN PHARMA

20MG/ML

N018768 001	Nov 10, 1983	Feb	CAHN
-------------	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSEN R AND D

25MG

N022187 003	Mar 26, 2012	Mar	NEWA
-------------	--------------	-----	------

100MG

N022187 001	Jan 18, 2008	Feb	CAHN
-------------	--------------	-----	------

+

200MG

N022187 002	Dec 22, 2010	Feb	CAHN
-------------	--------------	-----	------

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

7.5MG

N022334 004	Mar 30, 2012	Apr	NEWA
-------------	--------------	-----	------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+	AMYLIN	2MG/VIAL	N022200 001	Jan 27, 2012	Jan	NEWA
---	--------	----------	-------------	--------------	-----	------

EZETIMIBE

TABLET; ORAL

ZETIA

+	MSD INTL GMBH	10MG	N021445 001	Oct 25, 2002	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

+	MSP SINGAPORE	10MG	N021445 001	Oct 25, 2002	Jan	CAHN
---	---------------	------	-------------	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL

10MG;10MG

N021687 001 Jul 23, 2004 Jan CAHN

10MG;20MG

N021687 002 Jul 23, 2004 Jan CAHN

10MG;40MG

N021687 003 Jul 23, 2004 Jan CAHN

+		10MG;80MG	N021687 004	Jul 23, 2004	Jan	CAHN
---	--	-----------	-------------	--------------	-----	------

EZOGABINE

TABLET; ORAL

POTIGA

>A> GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011 May CAHN

>A> 200MG

N022345 002 Jun 10, 2011 May CAHN

>A> 300MG

N022345 003 Jun 10, 2011 May CAHN

>A> + 400MG

N022345 004 Jun 10, 2011 May CAHN

>D> VALEANT PHARMS 50MG

N022345 001 Jun 10, 2011 May CAHN

>D> 200MG

N022345 002 Jun 10, 2011 May CAHN

>D> 300MG

N022345 003 Jun 10, 2011 May CAHN

>D> + 400MG

N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB MACLEODS PHARMS LTD 125MG

A201022 001 Jan 12, 2012 Jan NEWA

AB 250MG

A201022 002 Jan 12, 2012 Jan NEWA

AB 500MG

A201022 003 Jan 12, 2012 Jan NEWA

FAMOTIDINE

TABLET; ORAL

PEPCID

AB MARATHON PHARMS 20MG

N019462 001 Oct 15, 1986 Jan CAHN

AB + 40MG

N019462 002 Oct 15, 1986 Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

@ UCB INC

20MG

N021712 001 Sep 24, 2004 Jan CAHN

@

40MG

N021712 002 Sep 24, 2004 Jan CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009 Apr CAHN

+		80MG	N021856 002	Feb 13, 2009	Apr	CAHN
---	--	------	-------------	--------------	-----	------

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB	LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
AB	+	130MG	N021695 003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

AB	DR REDDYS LABS SA	43MG	A090859 001	Mar 01, 2012	Feb	NEWA
AB		130MG	A090859 002	Mar 01, 2012	Feb	NEWA

TABLET; ORAL

FENOFIBRATE

>D>	AB	+	IMPAX LABS	160MG	A076509 002	Mar 26, 2008	May	CRLD
>A>	AB			160MG	A076509 002	Mar 26, 2008	May	CRLD
	AB	+		160MG	A076509 002	Mar 26, 2008	Mar	CRLD
>D>		@	TEVA	54MG	A076433 001	May 13, 2005	May	CMFD
>A>	AB			54MG	A076433 001	May 13, 2005	May	CMFD
		@		54MG	A076433 001	May 13, 2005	Mar	DISC
>D>		@		160MG	A076433 002	May 13, 2005	May	CMFD
>A>	AB	+		160MG	A076433 002	May 13, 2005	May	CMFD
		@		160MG	A076433 002	May 13, 2005	Mar	DISC
	AB		VALEANT INTL	48MG	A090715 001	Apr 05, 2012	Mar	NEWA
	AB			145MG	A090715 002	Apr 05, 2012	Mar	NEWA

FENTANYL

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

		0.1MG	N202788 001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788 001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788 002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788 002	Jan 04, 2012	Jan	NEWA
	+	0.4MG	N202788 003	Jan 04, 2012	Mar	CPOT
	+	0.4MCG	N202788 003	Jan 04, 2012	Jan	NEWA
		0.6MG	N202788 004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788 004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788 005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788 005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES

		EQ 0.1MG BASE	N022569 001	Jun 30, 2011	Jan	CPOT
	+	EQ 0.4MG BASE	N022569 002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Apr	NEWA
+		10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA
---	----------------------	----------------------	-------------	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------------------	-------------	--------------	-----	------

AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA
----	--	----------------------	-------------	--------------	-----	------

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------------------	-------------	--------------	-----	------

AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA
----	--	----------------------	-------------	--------------	-----	------

TABLET; ORAL

FLUCONAZOLE

@	PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
---	-------	------	-------------	--------------	-----	------

@		100MG	A076424 002	Jul 29, 2004	Feb	DISC
---	--	-------	-------------	--------------	-----	------

@		150MG	A076424 003	Jul 29, 2004	Feb	DISC
---	--	-------	-------------	--------------	-----	------

@		200MG	A076424 004	Jul 29, 2004	Feb	DISC
---	--	-------	-------------	--------------	-----	------

@	RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
---	------------------	------	-------------	--------------	-----	------

@		100MG	A076386 002	Jul 29, 2004	Apr	DISC
---	--	-------	-------------	--------------	-----	------

@		150MG	A076386 003	Jul 29, 2004	Apr	DISC
---	--	-------	-------------	--------------	-----	------

@		200MG	A076386 004	Jul 29, 2004	Apr	DISC
---	--	-------	-------------	--------------	-----	------

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@	GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar	DISC
---	--------------	-----------	-------------	--------------	-----	------

FLUDARABINE PHOSPHATE

AP	+ HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar	CRLD
----	-----------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OFORTA

>D>						
-----	--	--	--	--	--	--

>D>	+ SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	May	DISC
-----	---------------------	------	-------------	--------------	-----	------

>A>	@	10MG	N022273 001	Dec 18, 2008	May	DISC
-----	---	------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

@	TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Jan	DISC
---	-----------------	----------------------	-------------	--------------	-----	------

@		1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Jan	DISC
---	--	---------------------	-------------	--------------	-----	------

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

>D>	@ ACTAVIS MID ATLANTIC	0.05%	A074204 001	Jun 13, 1995	May	CAHN
-----	------------------------	-------	-------------	--------------	-----	------

AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

>A>	@ G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995	May	CAHN
-----	--------------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

FLUOROPLEX

+	AQUA PHARMS	1%	N016988 001		Jan	CAHN
---	-------------	----	-------------	--	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
-----	------------------	--------------	-------------	--------------	-----	------

AB1		EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
-----	--	--------------	-------------	--------------	-----	------

AB	+	EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
----	---	--------------	-------------	--------------	-----	------

@		EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN
---	--	--------------	-------------	--------------	-----	------

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
-----	------------------	--------------	-------------	--------------	-----	------

AB2	+	EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN
-----	---	--------------	-------------	--------------	-----	------

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

	WATSON PHARMS	0.05%	N012806 002		Apr	CMFD
--	---------------	-------	-------------	--	-----	------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
----	---	----------------------	-------	-------------	--------------	-----	------

AB		SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD
----	--	------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
----	--	------------------	--------------	-------------	--------------	-----	------

AB			EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

>A>	AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
-----	----	-------------	--------------	-------------	--------------	-----	------

>A>	AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

LESCOL

AB		NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
----	--	----------	--------------	-------------	--------------	-----	------

AB	+		EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG
----	---	--	--------------	-------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
---	------------------	------	-------------	--------------	-----	------

@		20MG	A076580 002	Apr 23, 2004	Apr	DISC
---	--	------	-------------	--------------	-----	------

@		40MG	A076580 003	Apr 23, 2004	Apr	DISC
---	--	------	-------------	--------------	-----	------

TABLET; ORAL

MONOPRIL

@ BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
@	20MG	N019915 003	May 16, 1991	Mar	DISC
@	40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC
-------------------	-------------------------	-------------	--------------	-----	------

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
@	500MG	A076457 002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN	
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN	
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN	
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	+	APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@	TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
----	---	---------------------	-----------	-------------	--------------	-----	------

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

	@		10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
--	---	--	--------------------	-------------	--------------	-----	------

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

>D>	+	GE HEALTHCARE	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
-----	---	---------------	------------	-------------	--------------	-----	------

>A>	+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
-----	---	---------------	------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	--	----------------------	--------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar	CFTG
----	---	----------------	--------------	-------------	--------------	-----	------

AB	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Mar	CFTG
----	---	--	--------------	-------------	--------------	-----	------

	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Feb	CRLD
--	---	--	--------------	-------------	--------------	-----	------

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
----	--	------	--------------	-------------	--------------	-----	------

AB			12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

	@		25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC
--	---	--	------------	-------------	--------------	-----	------

			25MG;300MG	A077369 003	Mar 30, 2012	Mar	NEWA
--	--	--	------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
----	--	-------------	-------------	-------------	--------------	-----	------

AB			12.5MG;100MG	A091617 002	Feb 17, 2012	Feb	NEWA
----	--	--	--------------	-------------	--------------	-----	------

AB			25MG;100MG	A091617 003	Feb 17, 2012	Feb	NEWA
----	--	--	------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
	12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
+	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Apr	CRLD
	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ PADDOCK LLC	12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
@	12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
@	25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692 001		Jan	CAHN
----	---	----------------	----	-------------	--	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505 001		Jan	CAHN
----	--	----------------	--------	-------------	--	-----	------

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

LOCOID

>A>	+	PRECISION DERMAT	0.1%	N022076 001	May 18, 2007	May	CAHN
-----	---	------------------	------	-------------	--------------	-----	------

>D>	+	TRIAx PHARMS LLC	0.1%	N022076 001	May 18, 2007	May	CAHN
-----	---	------------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

LOCOID

>A>	AB	+	PRECISION DERMAT	0.1%	N018652 001	Oct 29, 1982	May	CAHN
-----	----	---	------------------	------	-------------	--------------	-----	------

>D>	AB	+	TRIAx PHARMS LLC	0.1%	N018652 001	Oct 29, 1982	May	CAHN
-----	----	---	------------------	------	-------------	--------------	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB	+	TARO	0.2%	A075042 001	Aug 25, 1998	Mar	CRLD
----	---	------	------	-------------	--------------	-----	------

WESTCORT

@ RANBAXY	0.2%	N017950 001		Mar	DISC
-----------	------	-------------	--	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+	SHIRE LLC	50MG	N011949 001		Jan	CAHN
----	---	-----------	------	-------------	--	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC 10MG/5ML

A086880 001		Feb	CAHN
-------------	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
----	---	-------------------	---------------	-------------	--------------	-----	------

IBANDRONATE SODIUM

AB		APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
---	--------------	------------------------------------	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@ TEVA PARENTERAL 5MG/VIAL

A065037 003	May 01, 2002	Mar	DISC
-------------	--------------	-----	------

@ 10MG/VIAL

A065037 002	May 01, 2002	Mar	DISC
-------------	--------------	-----	------

@ 20MG/VIAL

A065037 001	May 01, 2002	Mar	DISC
-------------	--------------	-----	------

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB		PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB			25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB			50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB		APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB		FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB		GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
+	0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

IRBESARTAN

TABLET; ORAL

AVAPRO

AB	SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
	@ TEVA PARENTERAL	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC
-----------------	------	-------------	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL

>A>	ABSORICA					
>A>	CIPHER	10MG	N021951 001	May 25, 2012	May	NEWA
>A>		20MG	N021951 002	May 25, 2012	May	NEWA
>A>		30MG	N021951 003	May 25, 2012	May	NEWA
>A>		40MG	N021951 004	May 25, 2012	May	NEWA

MYORISAN

AB	DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485 003	Jan 19, 2012	Jan	NEWA

IVACAFTOR

TABLET; ORAL

KALYDECO

+	VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	---------------	-------	-------------	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL

SKLICE

+	SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
---	----------------	------	-------------	--------------	-----	------

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
----	----------------------	-------------	-------------	--------------	-----	------

AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA
----	-----------	-------------	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
----	-------------------	------	-------------	--------------	-----	------

AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB		200MG	A090169 004	May 12, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

>D>	+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
-----	---	-----------	--------------	-------------	--------------	-----	------

	+		EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
--	---	--	--------------	-------------	--------------	-----	------

>D>	+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
-----	---	--	--------------	-------------	--------------	-----	------

	+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
--	---	--	--------------	-------------	--------------	-----	------

>D>	+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN
-----	---	--	---------------	-------------	--------------	-----	------

	+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
--	---	--	---------------	-------------	--------------	-----	------

>A>	+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
-----	---	--------------	--------------	-------------	--------------	-----	------

>A>	+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
-----	---	--	--------------	-------------	--------------	-----	------

>A>	+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN
-----	---	--	---------------	-------------	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
----	-------------------	------	-------------	--------------	-----	------

AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN
----	---	------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@ TEVA PHARMS

15MG

A078730 001	Oct 15, 2010	Mar	DISC
-------------	--------------	-----	------

@

30MG

A078730 002	Oct 15, 2010	Mar	DISC
-------------	--------------	-----	------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL
PREVACID

TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
+	30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
FOSRENOL

@ SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
	EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
	EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+	EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LETROZOLE

TABLET; ORAL
LETROZOLE

AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
----	------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
@ TEVA PARENTERAL

EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993	Mar	DISC
-------------------	-------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT

>A>	+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011 001	Oct 22, 1990	May	CAHN
>A>	+		7.5MG/VIAL	N019732 001	Jan 26, 1989	May	CAHN
>A>	+		11.25MG/VIAL	N020708 001	Mar 07, 1997	May	CAHN
>D>	+	ABBOTT LABS	3.75MG/VIAL	N020011 001	Oct 22, 1990	May	CAHN
>D>	+		7.5MG/VIAL	N019732 001	Jan 26, 1989	May	CAHN
>D>	+		11.25MG/VIAL	N020708 001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
LEVETIRACETAM

>A>	AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010	May	CAHN
	AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869 001	Apr 06, 2012	Mar	NEWA
>D>	AP	NEXUS PHARMS	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010	May	CAHN
	AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Jan	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601 001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079 001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	WATSON LABS INC	250MG	A078797 002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797 003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797 004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

>A>	AB	BOCA PHARMA	500MG	A201464 001	May 25, 2012	May	NEWA
>A>	AB		750MG	A201464 002	May 25, 2012	May	NEWA
>A>	AB	TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012	May	NEWA
>A>	AB		750MG	A091338 002	May 29, 2012	May	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA

LEVONORGESTREL

TABLET; ORAL

PLAN B

>A>	AB	+	TEVA BRANDED PHARM	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
>A>			@	0.75MG	N021045 001	Jul 28, 1999	May	CAHN
>D>	AB	+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
>D>			@	0.75MG	N021045 001	Jul 28, 1999	May	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>			XYLOCAINE DENTAL					
>D>	AP	+	DENTSPLY PHARM	2%	N021380 001		May	DISC
>A>			@	2%	N021380 001		May	DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003	Jan	CAHN
----	----------------	-----------	-------------	--------------	-----	------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan	NEWA
		2.5MG;850MG	N201281 002	Jan 30, 2012	Jan	NEWA
	+	2.5MG;1GM	N201281 003	Jan 30, 2012	Jan	NEWA

LOMUSTINE

CAPSULE; ORAL

>D>			CEENU					
>D>			BRISTOL MYERS SQUIBB	10MG	N017588 001		May	DISC
>A>			@	10MG	N017588 001		May	DISC
>D>				40MG	N017588 002		May	DISC
>A>			@	40MG	N017588 002		May	DISC
>D>			+	100MG	N017588 003		May	DISC
>A>			+	@	N017588 003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169 001	Jan 30, 2012	Jan	NEWA
----	-------------------	--------	-------------	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

>A>	AB	MACLEODS PHARMS LTD	25MG	A202230 001	May 30, 2012	May	NEWA
>A>	AB		50MG	A202230 002	May 30, 2012	May	NEWA
>A>	AB		100MG	A202230 003	May 30, 2012	May	NEWA

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746 001	Mar 06, 2012	Apr	NEWA
---	----------------	-------	-------------	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Apr	NEWA
+		40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
		40GM/1000ML (40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN	
>A>	AT	SUVEN LIFE	0.5%	A091559 001	May 23, 2012	May	NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

>D>	+	PHARMAXIS	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010	May	CAHN
>A>	+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010	May	CAHN

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

>A>	+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN
>D>	+	TERCICA	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	-------------	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE									
	@ ORCHID HLTHCARE	5MG		A090044	001	Mar 12,	2012	Mar	DISC
AB		5MG		A090044	001	Mar 12,	2012	Feb	NEWA
	@	10MG		A090044	002	Mar 12,	2012	Mar	DISC
AB		10MG		A090044	002	Mar 12,	2012	Feb	NEWA
NAMENDA									
	FOREST LABS	5MG		N021487	001	Oct 16,	2003	Mar	CTEC
AB		5MG		N021487	001	Oct 16,	2003	Feb	CTEC
	+	10MG		N021487	002	Oct 16,	2003	Mar	CTEC
AB	+	10MG		N021487	002	Oct 16,	2003	Feb	CTEC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE									
>D>									
>D>	AP	DENTSPLY PHARM	3%	A088653	001	Aug 21,	1984	May	DISC
>A>		@	3%	A088653	001	Aug 21,	1984	May	DISC

MESALAMINE

SUPPOSITORY; RECTAL

ROWASA									
	@ MEDA PHARMS	500MG		N019919	001	Dec 18,	1990	Jan	CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA									
AP	MYLAN INSTITUTIONAL	100MG/ML		A076488	001	Mar 08,	2012	Feb	NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE									
AB	MARKSANS PHARMA	500MG		A090888	001	Mar 12,	2012	Feb	NEWA
AB		850MG		A090888	002	Mar 12,	2012	Feb	NEWA
AB		1GM		A090888	003	Mar 12,	2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE									
AB1	INVENTIA HLTHCARE	500MG		A201991	001	Jan 18,	2012	Jan	NEWA
	@ RANBAXY LABS LTD	500MG		A076413	001	Jun 18,	2004	Apr	DISC
	@	750MG		A077211	001	Jun 29,	2005	Apr	DISC

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE		N200678	001	Nov 05,	2010	Apr	CAIN
		1GM;EQ 2.5MG BASE		N200678	003	Nov 05,	2010	Apr	CAIN
	+	1GM;EQ 5MG BASE		N200678	002	Nov 05,	2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

>D>		MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30,	2007	May	CAHN
>D>	+		1GM;EQ 50MG BASE	N022044	002	Mar 30,	2007	May	CAHN
>A>		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30,	2007	May	CAHN
>A>	+		1GM;EQ 50MG BASE	N022044	002	Mar 30,	2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068 002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001		Mar	CMFD
AA		750MG	A086988 001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

@

METHYCLOTHIAZIDE

AB	+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	---	------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

>D>	PROGENICS	8MG/0.4ML	N021964 002	Sep 27, 2010	May	CAHN
>A>	SALIX PHARMS	8MG/0.4ML	N021964 002	Sep 27, 2010	May	CAHN

SOLUTION; SUBCUTANEOUS

RELISTOR

>D>	+	PROGENICS	12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008	May	CAHN
>A>	+	SALIX PHARMS	12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB			10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB			20MG	A090710 003	Mar 15, 2012	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

@ TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC
-------------------	--------------------	-------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
-------------------	----------------	-------------	--------------	-----	------

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
	+	NORITATE					
	+	VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

METYROSINE

CAPSULE; ORAL

DEMSE

>D>	+	ATON	250MG	N017871 001		May	CAHN
>A>	+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP			EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB		SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+		5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB			10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
---	----------------	-------	-------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

>A>	AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
>A>		@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN
>A>	AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN
>D>	AB	TRIAx PHARMS LLC	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
>D>		@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN
>D>	AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN

INJECTABLE; INJECTION

MINOCIN

>A>	+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN
>D>	+	TRIAx PHARMS LLC	EQ 100MG BASE/VIAL	N050444 001		May	CAHN

SUSPENSION; ORAL

MINOCIN

>A>	@	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN
>D>	@	TRIAx PHARMS	EQ 50MG BASE/5ML	N050445 001		May	CAHN

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
---	---------------	------------	-------------	--------------	-----	------

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

ELOCON

>A>	AB	+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987	May	CAHN
>D>	AB	+	SCHERING	0.1%	N019543 001	Apr 30, 1987	May	CAHN

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

>D>	+	EKR THERAP	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
>D>	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
>D>	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN
>A>	@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
>A>	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
>A>	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
AB			30MG	A078761 002	May 11, 2012	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB	RANBAXY LABS LTD	60MG	A078761 003	May 11, 2012	Apr	NEWA
AB		100MG	A078761 004	May 11, 2012	Apr	NEWA
AB		200MG	A078761 005	May 11, 2012	Apr	NEWA
>D>	ORAMORPH SR					
>D>	BC XANODYNE PHARM	15MG	N019977 004	Nov 23, 1994	May	DISC
>D>	BC	30MG	N019977 001	Aug 15, 1991	May	DISC
>D>	BC	60MG	N019977 002	Aug 15, 1991	May	DISC
>D>	BC +	100MG	N019977 003	Aug 15, 1991	May	DISC
>A>	@ XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
>A>	@	30MG	N019977 001	Aug 15, 1991	May	DISC
>A>	@	60MG	N019977 002	Aug 15, 1991	May	DISC
>A>	@	100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCIIN

OINTMENT; TOPICAL

MUPIROCIIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

>A>	AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001	May	CAHN
>D>	AB	ROCHE PALO	EQ 250MG BASE	N018164 001	May	CAHN
		ANAPROX DS				
>A>	AB	+ HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May CAHN
>D>	AB	+ ROCHE PALO	EQ 500MG BASE	N018164 003	Sep 30, 1987	May CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

>D>	+	GLAXOSMITHKLINE	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May CAHN
>A>	+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

>A>	AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May NEWA
>A>	AB		EQ 2.5MG BASE	A202431 002	May 31, 2012	May NEWA

TABLET; ORAL

NARATRIPTAN

AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA

NEVIRAPINE

SUSPENSION; ORAL

>A>	NEVIRAPINE					
>A>	AA	AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May NEWA
		VIRAMUNE				
>D>	+	BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May CFTG
>A>	AA	+	50MG/5ML	N020933 001	Sep 11, 1998	May CFTG

TABLET; ORAL

>A>	NEVIRAPINE					
>A>	AB	APOTEX INC	200MG	A203021 001	May 22, 2012	May NEWA
>A>	AB	AUROBINDO	200MG	A077521 001	May 22, 2012	May NEWA
>A>	AB	CIPLA	200MG	A077956 001	May 22, 2012	May NEWA
>A>	AB	HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May NEWA
>A>	AB	MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May NEWA
>A>	AB	MYLAN LABS	200MG	A078864 001	May 22, 2012	May NEWA
>A>	AB	MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May NEWA
>A>	AB	PRINSTON INC	200MG	A078644 001	May 22, 2012	May NEWA
>A>	AB	SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May NEWA
>A>	AB	STRIDES	200MG	A078195 001	May 22, 2012	May NEWA
		VIRAMUNE				
>D>	+	BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May CFTG
>A>	AB	+	200MG	N020636 001	Jun 21, 1996	May CFTG

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

>A>	AB1	ACTAVIS	90MG	A077899 003	May 25, 2012	May NEWA
-----	-----	---------	------	-------------	--------------	----------

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

	@	RANBAXY LABS LTD	75MG;25MG	A076951 001	Mar 30, 2005	Apr DISC
--	---	------------------	-----------	-------------	--------------	----------

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

+	APTALIS PHARMA	0.4%	N021359 001	Jun 21, 2011	Jan CAHN
---	----------------	------	-------------	--------------	----------

NIZATIDINE

CAPSULE; ORAL

AXID

	@	SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988	Mar DISC
--	---	--------------------	-------	-------------	--------------	----------

	@		300MG	N019508 002	Apr 12, 1988	Mar DISC
--	---	--	-------	-------------	--------------	----------

NIZATIDINE

	@	MYLAN PHARMS INC	150MG	A075934 001	Jul 09, 2002	Apr DISC
--	---	------------------	-------	-------------	--------------	----------

AB	+		300MG	A075806 002	Jul 05, 2002	Apr CRLD
----	---	--	-------	-------------	--------------	----------

	@		300MG	A075934 002	Jul 09, 2002	Apr DISC
--	---	--	-------	-------------	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

>A>	AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	May	CAHN
>D>	AP	SINTETICA	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	May	CAHN
	AP		EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	Mar	NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT		FOUGERA PHARMS	100,000 UNITS/GM	A062129 001		Jan	CAHN
----	--	----------------	------------------	-------------	--	-----	------

OINTMENT; TOPICAL

NYSTATIN

AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124 002	Sep 23, 1982	Jan	CAHN
----	---	----------------	------------------	-------------	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD

200MG

A076220 001 Sep 02, 2003 Apr DISC

@

300MG

A076220 002 Sep 02, 2003 Apr DISC

@

400MG

A076220 003 Sep 02, 2003 Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP		PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
----	--	-------------	-----------	-------------	--------------	-----	------

AP		SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN
----	--	------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OLANZAPINE

AB		APOTEX INC	2.5MG	A090798 001	Apr 23, 2012	Apr	NEWA
----	--	------------	-------	-------------	--------------	-----	------

AB			5MG	A090798 002	Apr 23, 2012	Apr	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			7.5MG	A090798 003	Apr 23, 2012	Apr	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			10MG	A090798 004	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			15MG	A090798 005	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			20MG	A090798 006	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB		AUROBINDO PHARMA LTD	2.5MG	A202050 001	Apr 23, 2012	Apr	NEWA
----	--	----------------------	-------	-------------	--------------	-----	------

AB			5MG	A202050 002	Apr 23, 2012	Apr	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			7.5MG	A202050 003	Apr 23, 2012	Apr	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			10MG	A202050 004	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			15MG	A202050 005	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			20MG	A202050 006	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB		DR REDDYS LABS LTD	2.5MG	A076255 001	Apr 23, 2012	Apr	NEWA
----	--	--------------------	-------	-------------	--------------	-----	------

AB			5MG	A076255 002	Apr 23, 2012	Apr	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			7.5MG	A076255 003	Apr 23, 2012	Apr	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			10MG	A076255 004	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			15MG	A076133 001	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB		MYLAN	2.5MG	A076866 001	Apr 23, 2012	Apr	NEWA
----	--	-------	-------	-------------	--------------	-----	------

AB			5MG	A076866 002	Apr 23, 2012	Apr	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			7.5MG	A076866 003	Apr 23, 2012	Apr	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			10MG	A076866 004	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			15MG	A076866 005	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			20MG	A076866 006	Apr 23, 2012	Apr	NEWA
----	--	--	------	-------------	--------------	-----	------

AB		ORCHID HLTHCARE	2.5MG	A202287 001	Apr 23, 2012	Apr	NEWA
----	--	-----------------	-------	-------------	--------------	-----	------

AB			5MG	A202287 002	Apr 23, 2012	Apr	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			7.5MG	A202287 003	Apr 23, 2012	Apr	NEWA
----	--	--	-------	-------------	--------------	-----	------

TABLET; ORAL

OLANZAPINE

AB	ORCHID HLTHCARE	10MG	A202287 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287 006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038 006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091434 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+		100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
ANTUROL

+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@	JANSSEN PHARMS	5MG	N017577 001		Mar	DISC
---	----------------	-----	-------------	--	-----	------

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
---	------------	---------	-------------	--------------	-----	------

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

>D> OPANA ER

>D>	AB		ENDO PHARMS	5MG	N021610 001	Jun 22, 2006	May	DISC
-----	----	--	-------------	-----	-------------	--------------	-----	------

>A>		@		5MG	N021610 001	Jun 22, 2006	May	DISC
-----	--	---	--	-----	-------------	--------------	-----	------

>D>	AB			10MG	N021610 002	Jun 22, 2006	May	DISC
-----	----	--	--	------	-------------	--------------	-----	------

>A>		@		10MG	N021610 002	Jun 22, 2006	May	DISC
-----	--	---	--	------	-------------	--------------	-----	------

>D>	AB			20MG	N021610 003	Jun 22, 2006	May	DISC
-----	----	--	--	------	-------------	--------------	-----	------

>A>		@		20MG	N021610 003	Jun 22, 2006	May	DISC
-----	--	---	--	------	-------------	--------------	-----	------

>D>	AB			30MG	N021610 007	Feb 29, 2008	May	DISC
-----	----	--	--	------	-------------	--------------	-----	------

>A>		@		30MG	N021610 007	Feb 29, 2008	May	DISC
-----	--	---	--	------	-------------	--------------	-----	------

>D>	AB	+		40MG	N021610 004	Jun 22, 2006	May	DISC
-----	----	---	--	------	-------------	--------------	-----	------

>A>		@		40MG	N021610 004	Jun 22, 2006	May	DISC
-----	--	---	--	------	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

>D>	AB		IMPAX LABS	5MG	A079087 001	Jun 14, 2010	May	CTEC
-----	----	--	------------	-----	-------------	--------------	-----	------

>A>				5MG	A079087 001	Jun 14, 2010	May	CTEC
-----	--	--	--	-----	-------------	--------------	-----	------

>D>	AB			10MG	A079087 003	Jun 14, 2010	May	CTEC
-----	----	--	--	------	-------------	--------------	-----	------

>A>				10MG	A079087 003	Jun 14, 2010	May	CTEC
-----	--	--	--	------	-------------	--------------	-----	------

>D>	AB			20MG	A079087 005	Jun 14, 2010	May	CTEC
-----	----	--	--	------	-------------	--------------	-----	------

>A>				20MG	A079087 005	Jun 14, 2010	May	CTEC
-----	--	--	--	------	-------------	--------------	-----	------

>D>	AB			30MG	A079087 006	Jul 22, 2010	May	CTEC
-----	----	--	--	------	-------------	--------------	-----	------

>A>				30MG	A079087 006	Jul 22, 2010	May	CTEC
-----	--	--	--	------	-------------	--------------	-----	------

>D>	AB			40MG	A079087 007	Jun 14, 2010	May	CTEC
-----	----	--	--	------	-------------	--------------	-----	------

>A>				40MG	A079087 007	Jun 14, 2010	May	CTEC
-----	--	--	--	------	-------------	--------------	-----	------

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@	TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	Jan	DISC
---	-----------------	---------------------------------	-------------	--------------	-----	------

@		100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC
---	--	------------------------------------	-------------	--------------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA

6MG/ML

N020262 001 Dec 29, 1992 Mar CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991 Mar DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

30,000USP UNITS;6,000USP
UNITS;19,000USP UNITS

N020725 001 Apr 30, 2009 Feb CAHN

60,000USP UNITS;12,000USP
UNITS;38,000USP UNITS

N020725 002 Apr 30, 2009 Feb CAHN

+

120,000USP UNITS;24,000USP
UNITS;76,000USP UNITS

N020725 003 Apr 30, 2009 Feb CAHN

>A>

PERTZYE

>A>

DIGESTIVE CARE INC

30,250USP/UNITS;8,000USP/UNITS;28
,750USP/UNITS

N022175 001 May 17, 2012 May NEWA

>A>

+

60,500USP/UNITS;16,000USP/UNITS;5
7,500USP/UNITS

N022175 002 May 17, 2012 May NEWA

ULTRESA

APTALIS PHARMA US

27,600USP UNITS;13,800USP
UNITS;27,600USP UNITS

N022222 001 Mar 01, 2012 Mar NEWA

41,400USP UNITS;20,700USP
UNITS;41,400USP UNITS

N022222 002 Mar 01, 2012 Mar NEWA

+

46,000USP UNITS;23,000USP
UNITS;46,000USP UNITS

N022222 003 Mar 01, 2012 Mar NEWA

ZENPEP

APTALIS PHARMA US

16,000USP UNITS;3,000USP
UNITS;10,000USP UNITS

N022210 005 Jun 15, 2011 Apr NEWA

109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009 Apr CRLD

+

136,000USP UNITS;25,000USP
UNITS;85,000USP UNITS

N022210 006 Jul 13, 2011 Apr NEWA

TABLET; ORAL

VIOKACE

APTALIS PHARMA US

39,150USP UNITS;10,440USP
UNITS;39,150USP UNITS

N022542 001 Mar 01, 2012 Mar NEWA

+

78,300USP UNITS;20,880USP
UNITS;78,300USP UNITS

N022542 002 Mar 01, 2012 Mar NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB APOTEX INC

EQ 20MG BASE

A090807 001 May 02, 2012 Apr NEWA

AB

EQ 40MG BASE

A090807 002 May 02, 2012 Apr NEWA

AB

MACLEODS PHARMS LTD

EQ 20MG BASE

A200821 001 Feb 16, 2012 Jan NEWA

AB

EQ 40MG BASE

A200821 002 Feb 16, 2012 Jan NEWA

AB

RANBAXY LABS LTD

EQ 20MG BASE

A200794 001 May 02, 2012 Apr NEWA

AB

EQ 40MG BASE

A200794 002 May 02, 2012 Apr NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH

EQ 10MG BASE

A076968 001 Jun 21, 2010 Feb CMFD

AB

EQ 20MG BASE

A076968 002 Jun 21, 2010 Feb CMFD

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

>D>	+	EYETECH INC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
>A>	+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

>D>	AB	+	ALLERGAN	5%	N019855 001	Aug 25, 1989	May	CAHN
>A>	AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
----	---------	------	-------------	--------------	-----	------

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ SANDOZ INC 30MG

A088605 001 Sep 28, 1987 Feb DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

CITIUS PHARMS 30MG

N202088 002 Jun 13, 2011 Apr CRLD

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

+	CITIUS PHARMS	37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
		37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
----	---	-----------------	-----------	-------------	--	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

>D>		@ GENPHARM	5MG	A074013 001	Sep 24, 1992	May	CAHN
>D>		@	10MG	A074018 001	Sep 24, 1992	May	CAHN
>A>		@ MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992	May	CAHN
>A>		@	10MG	A074018 001	Sep 24, 1992	May	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

		TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
			EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
+			EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

		@ FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987	Mar	DISC
		KAON CL-10					
		@ SAVAGE LABS	10MEQ	N017046 002		Mar	DISC
		KLOR-CON M20					
AB	+	UPSHER-SMITH LABS	20MEQ	A074726 001	Nov 20, 1998	Mar	CRLD
		KLOTRIX					
		@ APOTHECON	10MEQ	N017850 001		Mar	DISC
		POTASSIUM CHLORIDE					
		@ NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Mar	DISC
		@ SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
		@	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

		@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb	CAHN
		@	20MEQ/PACKET	N019647 001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr	NEWA
----	--	------------	---------	-------------	--------------	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA

SEROQUEL

AB	+	ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB			EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB			EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB			EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+		EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB			EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009 Apr DISC

@

10MG

A078849 002 Mar 06, 2009 Apr DISC

TABLET; ORAL

ALTACE

@ KING PFIZER

1.25MG

N022021 001 Feb 27, 2007 Jan DISC

@

2.5MG

N022021 002 Feb 27, 2007 Jan DISC

@

5MG

N022021 003 Feb 27, 2007 Jan DISC

@

10MG

N022021 004 Feb 27, 2007 Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
		ZANTAC IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
		@	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB	PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

>A>	AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
>A>	AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
>A>	AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
>A>	AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB			EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB			EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB			EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB			EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

	AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
	AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
	AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
	AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
	AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
>A>	AB		EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
>A>	AB		EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
>A>	AB		EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
>A>	AB		EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
>A>	AB	SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
>A>	AB		EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
>A>	AB		EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
>A>	AB		EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
>A>	AB		EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
>A>	AB	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
>A>	AB		EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
>A>	AB		EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
>A>	AB		EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
>A>	AB		EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA

ROTIGOTINEFILM, EXTENDED RELEASE; TRANSDERMAL
NEUPRO

UCB INC	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
	2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
	3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
	4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
	6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+	8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SERTACONAZOLE NITRATECREAM; TOPICAL
ERTACZO

+ VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
----------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

>D>	MERCK CO INC	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
>D>		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
>D>	+	EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN
>A>	MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
>A>		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
>A>	+	EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC	460MG/GM; 420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--------------------	--------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

>D>	AB	GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
>A>	AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

>D>	AA	+	GE HEALTHCARE	100uCi	N017630 001		May	DISC
>A>			@	100uCi	N017630 001		May	DISC

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005 Feb CAHN

@

2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@

1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

@

1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

+

250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS 12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012 Feb NEWA

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

>A>	+	PARAPRO LLC	0.9%	N022408 001	Jan 18, 2011	May	CAHN
-----	---	-------------	------	-------------	--------------	-----	------

>D>	+	PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	May	CAHN
-----	---	----------------	------	-------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC 100MG

N019998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB FOUGERA PHARMS 10%

A077015 001 Nov 17, 2006 Jan CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+ JAZZ PHARMS COMMERCL 15%

N006530 003 Jan 27, 1987 Mar CAHN

SUPPOSITORY; VAGINAL

AVC

@ JAZZ PHARMS COMMERCL 1.05GM

N006530 004 Jan 27, 1987 Mar CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP INJECTALIA EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090310 001 Aug 11, 2010 Mar CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ MERCK SHARP DOHME 0.0015%

N202514 001 Feb 10, 2012 Feb NEWA

>A> TALIGLUCERASE ALFA

>A> POWDER; IV (INFUSION)

>A> ELELYSO

>A> + PFIZER 200 UNITS/VIAL

N022458 001 May 01, 2012 May NEWA

TAZAROTENE

>A> AEROSOL, FOAM; TOPICAL

>A> FABIOR

>A> + STIEFEL LABS INC 0.1%

N202428 001 May 11, 2012 May NEWA

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

>D> @ DRAXIMAGE N/A

N018035 001 May CAHN

>A> @ JUBILANT DRAXIMAGE N/A

N018035 001 May CAHN

DRAXIMAGE MDP-25

>D> + DRAXIMAGE N/A

N018035 002 Feb 27, 2004 May CAHN

>A> + JUBILANT DRAXIMAGE N/A

N018035 002 Feb 27, 2004 May CAHN

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SC00PFUL

N022577 001 Jan 18, 2012 Jan NEWA

TABLET; ORAL

VIREAD

GILEAD SCIENCES INC 150MG

N021356 002 Jan 18, 2012 Apr NEWA

200MG

N021356 003 Jan 18, 2012 Apr NEWA

250MG

N021356 004 Jan 18, 2012 Apr NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 1MG BASE

A076021 001 Aug 22, 2002 Apr DISC

@ EQ 2MG BASE

A076021 002 Aug 22, 2002 Apr DISC

@ EQ 5MG BASE

A076021 003 Aug 22, 2002 Apr DISC

@ EQ 10MG BASE

A076021 004 Aug 22, 2002 Apr DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ TEVA PARENTERAL 1MG/ML

A076853 001 Jul 20, 2004 Jan DISC

TERCONAZOLE

CREAM; VAGINAL							
TERCONAZOLE							
AB	FOUGERA PHARMS	0.4%	A076712	001	Feb 18, 2005	Jan	CAHN
SUPPOSITORY; VAGINAL							
TERCONAZOLE							
AB	FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Jan	CAHN

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS							
EGRIFTA							
>A>	+ EMD SERONO	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
>D>	+ THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN

TESTOSTERONE

GEL; TRANSDERMAL							
ANDROGEL							
ABBOTT LABS		1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Feb	CPOT
BX	+	1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Feb	CPOT
TESTIM							
BX	+ AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001	Oct 31, 2002	Feb	CPOT
TESTOSTERONE							
TEVA PHARMS		25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA
		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Feb	NEWA
PELLET; IMPLANTATION							
TESTOPEL							
>A>	+ ACTIENT PHARMS	75MG	A080911	001		May	CAHN
>D>	+ SLATE PHARMS	75MG	A080911	001		May	CAHN

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION							
TESTOSTERONE CYPIONATE							
AO	HIKMA FARMACEUTICA	200MG/ML	A091244	001	May 01, 2012	Apr	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION							
TESTOSTERONE ENANTHATE							
AO	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Feb	CAHN

TETRABENAZINE

TABLET; ORAL							
XENAZINE							
	VALEANT PHARMS	12.5MG	N021894	001	Aug 15, 2008	Apr	CAHN
	+	25MG	N021894	002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL							
TYZINE							
	+ FOUGERA PHARMS	0.05%	A086576	002		Jan	CAHN
		0.1%	A086576	001		Jan	CAHN
SPRAY; NASAL							
TYZINE							
	+ FOUGERA PHARMS	0.1%	A086576	003		Jan	CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

>D>	BC	UCB INC	100MG	A087942 001	Aug 22, 1983	May	CTEC
>A>			100MG	A087942 001	Aug 22, 1983	May	CTEC
>D>	BC		200MG	A087943 001	Aug 22, 1983	May	CTEC
>A>			200MG	A087943 001	Aug 22, 1983	May	CTEC
>D>	BC		300MG	A087944 001	Aug 22, 1983	May	CTEC
>A>			300MG	A087944 001	Aug 22, 1983	May	CTEC
>D>			400MG	A081034 001	Feb 28, 1992	May	CRLD
>A>	+		400MG	A081034 001	Feb 28, 1992	May	CRLD
>D>		THEOPHYLLINE					
>D>	BC	INWOOD LABS	100MG	A040052 001	Feb 14, 1994	May	DISC
>A>		@	100MG	A040052 001	Feb 14, 1994	May	DISC
>D>			125MG	A040052 002	Feb 14, 1994	May	DISC
>A>		@	125MG	A040052 002	Feb 14, 1994	May	DISC
>D>	BC		200MG	A040052 003	Feb 14, 1994	May	DISC
>A>		@	200MG	A040052 003	Feb 14, 1994	May	DISC
>D>	BC	+	300MG	A040052 004	Feb 14, 1994	May	DISC
>A>		@	300MG	A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
@		40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
@		80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
@		160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
@		200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
@		320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
@		400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@	CEPHALON	6MG	N020646 006	Nov 29, 2005	Jan	DISC
@		8MG	N020646 007	Nov 29, 2005	Jan	DISC
@		10MG	N020646 008	Nov 29, 2005	Jan	DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB	MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
AB	+	500MG	N021618 002	May 17, 2004	Apr	CFTG
	TINIDAZOLE					
AB	NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
AB		500MG	A202044 002	Apr 30, 2012	Apr	NEWA
AB	ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
AB		500MG	A201172 002	Apr 30, 2012	Apr	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA

CAPSULE; ORAL

ZANAFLEX

AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
	@ WATSON LABS	500MG	A086109 001		Mar	DISC
	@	500MG	A087318 001		Mar	DISC

TOLCAPONE

TABLET; ORAL

TASMAR

>D>	+	VALEANT PHARM INTL	100MG	N020697 001	Jan 29, 1998	May	CAHN
>D>		@	200MG	N020697 002	Jan 29, 1998	May	CAHN
>A>	+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
>A>		@	200MG	N020697 002	Jan 29, 1998	May	CAHN

TRAMADOL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

>A>	AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
>D>	AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
	AP		100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRETINOIN

CREAM; TOPICAL

RENOVA

	+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963 001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522 001		Jan	CAHN
AB	+		0.1%	N017340 001		Jan	CAHN

TRETINOIN

>A>	AB	PRECISION DERMAT	0.025%	A075264 001	Dec 24, 1998	May	CAHN
>A>	+		0.0375%	A090098 001	Mar 22, 2010	May	CAHN
>A>	AB1		0.05%	A075265 001	Dec 24, 1998	May	CAHN

CREAM; TOPICAL

TRETINOIN

>A>	AB	PRECISION DERMAT	0.1%	A075213 001	Dec 24, 1998	May	CAHN
>D>	AB2	SPEAR PHARMS	0.05%	A076498 001	Sep 15, 2005	May	CAHN
>A>	AB2	SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	May	CAHN
>D>	AB	TRIAX PHARMS LLC	0.025%	A075264 001	Dec 24, 1998	May	CAHN
>D>	+		0.0375%	A090098 001	Mar 22, 2010	May	CAHN
>D>	AB1		0.05%	A075265 001	Dec 24, 1998	May	CAHN
>D>	AB		0.1%	A075213 001	Dec 24, 1998	May	CAHN

GEL; TOPICAL

RETIN-A

	AB	+	VALEANT INTL	0.01%	N017955 001		Jan	CAHN
	AB	+		0.025%	N017579 002		Jan	CAHN

TRETINOIN

>A>	AB	PRECISION DERMAT	0.01%	A075589 001	Jun 11, 2002	May	CAHN
>A>	AB		0.025%	A075529 001	Feb 22, 2000	May	CAHN
>D>	AB	TRIAX PHARMS LLC	0.01%	A075589 001	Jun 11, 2002	May	CAHN
>D>	AB		0.025%	A075529 001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL

RETIN-A

	AT	+	VALEANT INTL	0.05%	N016921 001		Jan	CAHN
--	----	---	--------------	-------	-------------	--	-----	------

SWAB; TOPICAL

RETIN-A

		@	VALEANT INTL	0.05%	N016921 002		Jan	CAHN
--	--	---	--------------	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

>D>		AZMACORT						
>D>	+	ABBOTT	0.1MG/INH	N018117 001	Apr 23, 1982	May	DISC	
>A>	@		0.1MG/INH	N018117 001	Apr 23, 1982	May	DISC	

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		FOUGERA PHARMS	0.025%	A085692 001		Jan	CAHN
	AT			0.1%	A085692 003		Jan	CAHN
	AT	+		0.5%	A085692 002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN
	AT			0.1%	A040467 002	Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		FOUGERA PHARMS	0.025%	A085691 001		Jan	CAHN
	AT			0.1%	A085691 003		Jan	CAHN
	AT			0.5%	A085691 002		Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

	AB		TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar	CAHN
--	----	--	-------------	---------------	-------------	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

	AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar	NEWA
	AB			EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar	NEWA

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

>A>	+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May	CAHN
>D>	+	ROCHE PALO	50MG/ML	N022257 001	Aug 28, 2009	May	CAHN

TABLET; ORAL

VALCYTE

>A>	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May	CAHN
>D>	+	ROCHE PALO	EQ 450MG BASE	N021304 001	Mar 29, 2001	May	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB		VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
AB	+		EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB		AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
AB		STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
AB		WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

VANDETANIB

TABLET; ORAL

CAPRELSA

		IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
	+		300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB		BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB			5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB			10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+		20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB		TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB			5MG	A091347 002	May 03, 2012	Apr	NEWA
AB			10MG	A091347 003	May 03, 2012	Apr	NEWA
AB			20MG	A091347 004	May 03, 2012	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB			EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB			EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
		40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

>D>	+	PFIZER	200MG/VIAL	N021267 001	May 24, 2002	May	CFTG
>A>	AP	+	200MG/VIAL	N021267 001	May 24, 2002	May	CFTG
>A>		VORICONAZOLE					
>A>	AP	SANDOZ INC	200MG/VIAL	A090862 001	May 30, 2012	May	NEWA

TABLET; ORAL

VORICONAZOLE

AB	TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	Mar	NEWA
AB		200MG	A091658 002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN
---	----------------------	------------------------	-------------	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN
+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

@	RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005	Apr	DISC
---	------------------	-------	-------------	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05,	2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05,	2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05,	2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05,	2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02,	2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02,	2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02,	2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02,	2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02,	2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02,	2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02,	2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02,	2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02,	2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02,	2012	Feb	NEWA
AB			EQ 60MG BASE	A077560 003	Mar 02,	2012	Feb	NEWA
AB			EQ 80MG BASE	A077560 004	Mar 02,	2012	Feb	NEWA
>A>	AB	SANDOZ INC	EQ 20MG BASE	A077562 001	Jun 01,	2012	May	NEWA
>A>	AB		EQ 40MG BASE	A077562 002	Jun 01,	2012	May	NEWA
>A>	AB		EQ 60MG BASE	A077562 003	Jun 01,	2012	May	NEWA
>A>	AB		EQ 80MG BASE	A077562 004	Jun 01,	2012	May	NEWA

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+ MCNEIL CONS	800MG;10MG;165MG	N020958 001	Oct 16, 2000	Mar	CAHN
---------------	------------------	-------------	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCRUB MAXI SWABSTICK

+ PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Mar	CAHN
--------------	-------------------	-------------	--------------	-----	------

CHLORASCRUB SWAB

+ PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Mar	CAHN
--------------	-----------------	-------------	--------------	-----	------

CHLORASCRUB SWABSTICK

+ PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Mar	CAHN
--------------	-------------------	-------------	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

>A> TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135 001	May 25, 2012	May	NEWA
---------------------	-----------------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888 001	Mar 05, 2012	Feb	NEWA
---------------------	--	-------------	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS

+	10MG	N020801 001	Sep 24, 1998	Mar	CAHN
---	------	-------------	--------------	-----	------

+	20MG	N020801 002	Dec 17, 2007	Mar	CAHN
---	------	-------------	--------------	-----	------

TABLET; ORAL

PEPCID AC

MCNEIL CONS

+	10MG	N020325 001	Apr 28, 1995	Mar	CAHN
---	------	-------------	--------------	-----	------

+	20MG	N020325 002	Sep 23, 2003	Mar	CAHN
---	------	-------------	--------------	-----	------

PEPCID AC (GELTAB)

MCNEIL CONS	10MG	N020902 001	Aug 05, 1999	Mar	CAHN
-------------	------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567 002	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

WOCKHARDT LTD	30MG	A079112 002	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	30MG	A091567 001	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

WOCKHARDT LTD	30MG	A079112 001	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	60MG	A091567 004	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

SUN PHARM INDS	180MG	A091567 006	Feb 06, 2012	Jan	NEWA
----------------	-------	-------------	--------------	-----	------

WOCKHARDT LTD	60MG	A079112 004	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

WOCKHARDT LTD	180MG	A079112 006	Feb 08, 2012	Jan	NEWA
---------------	-------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567 003	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

SUN PHARM INDS	180MG	A091567 005	Feb 06, 2012	Jan	NEWA
----------------	-------	-------------	--------------	-----	------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE HIVES

WOCKHARDT LTD

60MG

A079112 003 Feb 08, 2012 Jan NEWA

180MG

A079112 005 Feb 08, 2012 Jan NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS

EQ 200MG FREE ACID AND POTASSIUM
SALT

A077338 001 Jul 10, 2009 Jan CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD

15MG

A202194 001 May 18, 2012 Apr NEWA

PERRIGO R AND D

15MG

A202319 001 May 18, 2012 Apr NEWA

WOCKHARDT LTD

15MG

A202727 001 May 18, 2012 Apr NEWA

PREVACID 24 HR

+ NOVARTIS

15MG

N022327 001 May 18, 2009 Apr CFTG

LEVONORGESTREL

TABLET; ORAL

PLAN B

>A>

+ TEVA BRANDED PHARM

0.75MG

N021045 002 Aug 24, 2006 May CAHN

>D>

+ TEVA WOMENS

0.75MG

N021045 002 Aug 24, 2006 May CAHN

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

AVEVA

7MG/24HR

A074612 002 Jul 28, 2003 Apr NEWA

14MG/24HR

A074612 003 Oct 20, 1997 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>A>

APOTEX INC

EQ 150MG BASE

A200172 001 May 31, 2012 May NEWA

SHASUN CHEMS

EQ 75MG BASE

A201745 001 Feb 29, 2012 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2012

NO MAY 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2012 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 32ND EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYL CYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	>A> 8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	>A> 8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	>A> 6667344	Jun 22, 2021	DP			
	>A> 6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	>A> 6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002	>A> 6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 003	>A> 6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	>A> 8168620	Feb 24, 2026	DP		>A> NC	May 01, 2015
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					>A> NCE	Mar 20, 2013
					>A> ODE	Mar 20, 2015
					>A> PED	Sep 20, 2015
					>A> PED	Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					>A> NCE	Mar 20, 2013
					>A> ODE	Mar 20, 2015
					>A> PED	Sep 20, 2015
					>A> PED	Sep 20, 2013
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	>A> 7717889	Feb 27, 2025	DP U-1022			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					>A> PC	Nov 13, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					>A> PC	Nov 13, 2012
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	>A> 8173158	Mar 17, 2030	U-951			
	>A> 8173158	Mar 17, 2030	U-950			
	>A> 8173158	Mar 17, 2030	U-949			
	>A> 8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	>A> 8173158	Mar 17, 2030	U-951			
	>A> 8173158	Mar 17, 2030	U-950			
	>A> 8173158	Mar 17, 2030	U-949			
	>A> 8173158*PED	Sep 17, 2030				
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001					NCE	May 20, 2016
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334	001				I-650 >A> ODE	Apr 26, 2015 Apr 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N022334	002				I-650 >A> ODE	Apr 26, 2015 Apr 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N022334	003	>A> 6004973	Jul 12, 2016	DP	I-650	Apr 26, 2015
		>A> 7297703	Dec 06, 2019	DP	>A> ODE	Apr 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N022334	004	5665772	Sep 09, 2019	DS DP	I-650	Apr 26, 2015
		6004973	Jul 12, 2016	DP	I-638	May 05, 2014
		7297703	Dec 06, 2019	DP	I-630	Oct 29, 2013
					NCE	Mar 30, 2014
					>A> ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200	001	5424286	Dec 01, 2016	U-1108	NP	Jan 27, 2015
		6479065	Aug 10, 2020	DP		
		6495164	May 25, 2020	DP		
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6858576	Jan 06, 2017	U-656		
		6872700	Jan 14, 2020	U-654		
		6956026	Jan 07, 2018	U-687		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP U-1223		
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP U-1223		
		7741269	Jan 07, 2018	U-1224		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	001				M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	002				M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445	001				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	001				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	002				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	003				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	004				M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-112	Feb 09, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	>A> 7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	>A> 7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	>A> 7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	>A> 7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	>A> 7579019	Jan 22, 2020	U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	>A> 5512570	Mar 04, 2014	U-850			
	>A> 5538982	Jul 23, 2013	U-850			
	>A> 5716942	Feb 10, 2015	U-850			
	>A> 7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8114909	Apr 11, 2026	U-1231			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 001	>A> 5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001					M-115	Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	>A> 7435427	Sep 21, 2021	DP		>A> NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	>A> 7435427	Sep 21, 2021	DP		>A> NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	>A> 7435427	Sep 21, 2021	DP		>A> NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	>A> 7435427	Sep 21, 2021	DP		>A> NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	8119648	Aug 12, 2023			U-774	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017			U-802	NCE
	6890898	Feb 02, 2019			U-1039	NC
	7078381	Feb 02, 2019			U-1039	
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019			U-1039	
	8119648	Aug 12, 2023			U-802	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017			U-802	NCE
	6890898	Feb 02, 2019			U-1039	NC
	7078381	Feb 02, 2019			U-1039	
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019			U-1039	
	8119648	Aug 12, 2023			U-802	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	002				D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	003				D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	004				D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	001				>A> M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	002				>A> M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	001	6303661	Apr 24, 2017	U-1227		
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP	U-1227	
		6890898	Feb 02, 2019		U-1228	
		7078381	Feb 02, 2019		U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Apr 11, 2026	DS DP	U-1227	
		7459428	Feb 02, 2019		U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	002	6303661	Apr 24, 2017	U-1227		
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP	U-1227	
		6890898	Feb 02, 2019		U-1228	
		7078381	Feb 02, 2019		U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Apr 11, 2026	DS DP	U-1227	
		7459428	Feb 02, 2019		U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	003	6303661	Apr 24, 2017	U-1227		
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP	U-1227	
		6890898	Feb 02, 2019		U-1228	
		7078381	Feb 02, 2019		U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Apr 11, 2026	DS DP	U-1227	
		7459428	Feb 02, 2019		U-1227	
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121	001	8163798	Jul 31, 2017	DP		
		8163798*PED	Jan 31, 2018			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121	002	8163798	Jul 31, 2017	DP		
		8163798*PED	Jan 31, 2018			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	>A> 6682348	Mar 29, 2022	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	>A> 8173172	Mar 17, 2018	DP			
	>A> 8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	>A> 8173172	Mar 17, 2018	DP			
	>A> 8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	8158156	Jun 19, 2027	U-1241			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	>A> 8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					>A> NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					>A> NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005					NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006					NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	>A> 6149938	Jul 23, 2018	DP U-1243			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	>A> 6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	>A> 6500454	Oct 04, 2021	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001					I-647	Apr 02, 2015
					I-646	Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002					I-647	Apr 02, 2015
					I-646	Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003					I-647	Apr 02, 2015
					I-646	Apr 02, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	>A> 8168637	Jun 26, 2022	DP	U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	>A> 8168637	Jun 26, 2022	DP	U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	>A> 8168637	Jun 26, 2022	DP	U-1188		
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8118771	Aug 10, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAFLOPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001					>A> NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					>A> NDF	May 11, 2015
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		ODE	May 30, 2014
	8026276*PED	Jul 20, 2026			PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 002	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-999	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-248	Y	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-250	Y	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001					NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					>A> PC	Aug 29, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560	002				>A> PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560	003				>A> PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560	004				>A> PC	Aug 29, 2012

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>